Report Detail
Global Antibody Drug Conjugates Market Insights, Forecast to 2025
- RnM2691873 |
- 04 June, 2019 |
- Global |
- 117 Pages |
- QYResearch |
- Pharma & Healthcare
Antibody Drug Conjugates are highly effective biopharmaceutical medications designed as a targeted therapy for cancer treatment.
The preparation process of ADC’s involves great difficulty, inspite of these hurdles recently approved ADC’s have proved their worth for treatment of cancer. Thus, there is a strong pipeline of ADC’s that promises revolutionary changes in area of targeted therapy for cancer treatment. This market is driven by elements such as continuous improvement in the clinical data and technological advancements in the field of drug development shelling out innovative drugs into the market.
The global Antibody Drug Conjugates market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Antibody Drug Conjugates market based on company, product type, end user and key regions.
This report studies the global market size of Antibody Drug Conjugates in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Antibody Drug Conjugates in these regions.
This research report categorizes the global Antibody Drug Conjugates market by top players/brands, region, type and end user. This report also studies the global Antibody Drug Conjugates market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
F. Hoffman-La Roche
Novartis AG
Takeda Pharmaceutical
Pfizer
Seattle Genetics
Genentech
Immunogen
Progenics Pharmaceuticals
Bayer Healthcare Pharmaceuticals
Market size by Product
Adcetris
Kadcyla
Market size by End User
Breast Cancer
Lymphoma
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Antibody Drug Conjugates market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Antibody Drug Conjugates market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Antibody Drug Conjugates companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Antibody Drug Conjugates submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Antibody Drug Conjugates are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Antibody Drug Conjugates market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Antibody Drug Conjugates Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Antibody Drug Conjugates Market Size Growth Rate by Product
- 1.4.2 Adcetris
- 1.4.3 Kadcyla
- 1.5 Market by End User
- 1.5.1 Global Antibody Drug Conjugates Market Size Growth Rate by End User
- 1.5.2 Breast Cancer
- 1.5.3 Lymphoma
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Antibody Drug Conjugates Market Size
- 2.1.1 Global Antibody Drug Conjugates Revenue 2014-2025
- 2.1.2 Global Antibody Drug Conjugates Sales 2014-2025
- 2.2 Antibody Drug Conjugates Growth Rate by Regions
- 2.2.1 Global Antibody Drug Conjugates Sales by Regions
- 2.2.2 Global Antibody Drug Conjugates Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Antibody Drug Conjugates Sales by Manufacturers
- 3.1.1 Antibody Drug Conjugates Sales by Manufacturers
- 3.1.2 Antibody Drug Conjugates Sales Market Share by Manufacturers
- 3.1.3 Global Antibody Drug Conjugates Market Concentration Ratio (CR5 and HHI)
- 3.2 Antibody Drug Conjugates Revenue by Manufacturers
- 3.2.1 Antibody Drug Conjugates Revenue by Manufacturers (2014-2019)
- 3.2.2 Antibody Drug Conjugates Revenue Share by Manufacturers (2014-2019)
- 3.3 Antibody Drug Conjugates Price by Manufacturers
- 3.4 Antibody Drug Conjugates Manufacturing Base Distribution, Product Types
- 3.4.1 Antibody Drug Conjugates Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Antibody Drug Conjugates Product Type
- 3.4.3 Date of International Manufacturers Enter into Antibody Drug Conjugates Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Antibody Drug Conjugates Sales by Product
- 4.2 Global Antibody Drug Conjugates Revenue by Product
- 4.3 Antibody Drug Conjugates Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Antibody Drug Conjugates Breakdown Data by End User
6 North America
- 6.1 North America Antibody Drug Conjugates by Countries
- 6.1.1 North America Antibody Drug Conjugates Sales by Countries
- 6.1.2 North America Antibody Drug Conjugates Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Antibody Drug Conjugates by Product
- 6.3 North America Antibody Drug Conjugates by End User
7 Europe
- 7.1 Europe Antibody Drug Conjugates by Countries
- 7.1.1 Europe Antibody Drug Conjugates Sales by Countries
- 7.1.2 Europe Antibody Drug Conjugates Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Antibody Drug Conjugates by Product
- 7.3 Europe Antibody Drug Conjugates by End User
8 Asia Pacific
- 8.1 Asia Pacific Antibody Drug Conjugates by Countries
- 8.1.1 Asia Pacific Antibody Drug Conjugates Sales by Countries
- 8.1.2 Asia Pacific Antibody Drug Conjugates Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Antibody Drug Conjugates by Product
- 8.3 Asia Pacific Antibody Drug Conjugates by End User
9 Central & South America
- 9.1 Central & South America Antibody Drug Conjugates by Countries
- 9.1.1 Central & South America Antibody Drug Conjugates Sales by Countries
- 9.1.2 Central & South America Antibody Drug Conjugates Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Antibody Drug Conjugates by Product
- 9.3 Central & South America Antibody Drug Conjugates by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Antibody Drug Conjugates by Countries
- 10.1.1 Middle East and Africa Antibody Drug Conjugates Sales by Countries
- 10.1.2 Middle East and Africa Antibody Drug Conjugates Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Antibody Drug Conjugates by Product
- 10.3 Middle East and Africa Antibody Drug Conjugates by End User
11 Company Profiles
- 11.1 F. Hoffman-La Roche
- 11.1.1 F. Hoffman-La Roche Company Details
- 11.1.2 Company Business Overview
- 11.1.3 F. Hoffman-La Roche Antibody Drug Conjugates Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 F. Hoffman-La Roche Antibody Drug Conjugates Products Offered
- 11.1.5 F. Hoffman-La Roche Recent Development
- 11.2 Novartis AG
- 11.2.1 Novartis AG Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Novartis AG Antibody Drug Conjugates Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Novartis AG Antibody Drug Conjugates Products Offered
- 11.2.5 Novartis AG Recent Development
- 11.3 Takeda Pharmaceutical
- 11.3.1 Takeda Pharmaceutical Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Takeda Pharmaceutical Antibody Drug Conjugates Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Takeda Pharmaceutical Antibody Drug Conjugates Products Offered
- 11.3.5 Takeda Pharmaceutical Recent Development
- 11.4 Pfizer
- 11.4.1 Pfizer Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Pfizer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Pfizer Antibody Drug Conjugates Products Offered
- 11.4.5 Pfizer Recent Development
- 11.5 Seattle Genetics
- 11.5.1 Seattle Genetics Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Seattle Genetics Antibody Drug Conjugates Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Seattle Genetics Antibody Drug Conjugates Products Offered
- 11.5.5 Seattle Genetics Recent Development
- 11.6 Genentech
- 11.6.1 Genentech Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Genentech Antibody Drug Conjugates Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Genentech Antibody Drug Conjugates Products Offered
- 11.6.5 Genentech Recent Development
- 11.7 Immunogen
- 11.7.1 Immunogen Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Immunogen Antibody Drug Conjugates Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Immunogen Antibody Drug Conjugates Products Offered
- 11.7.5 Immunogen Recent Development
- 11.8 Progenics Pharmaceuticals
- 11.8.1 Progenics Pharmaceuticals Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Progenics Pharmaceuticals Antibody Drug Conjugates Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Progenics Pharmaceuticals Antibody Drug Conjugates Products Offered
- 11.8.5 Progenics Pharmaceuticals Recent Development
- 11.9 Bayer Healthcare Pharmaceuticals
- 11.9.1 Bayer Healthcare Pharmaceuticals Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Bayer Healthcare Pharmaceuticals Antibody Drug Conjugates Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Bayer Healthcare Pharmaceuticals Antibody Drug Conjugates Products Offered
- 11.9.5 Bayer Healthcare Pharmaceuticals Recent Development
12 Future Forecast
- 12.1 Antibody Drug Conjugates Market Forecast by Regions
- 12.1.1 Global Antibody Drug Conjugates Sales Forecast by Regions 2019-2025
- 12.1.2 Global Antibody Drug Conjugates Revenue Forecast by Regions 2019-2025
- 12.2 Antibody Drug Conjugates Market Forecast by Product
- 12.2.1 Global Antibody Drug Conjugates Sales Forecast by Product 2019-2025
- 12.2.2 Global Antibody Drug Conjugates Revenue Forecast by Product 2019-2025
- 12.3 Antibody Drug Conjugates Market Forecast by End User
- 12.4 North America Antibody Drug Conjugates Forecast
- 12.5 Europe Antibody Drug Conjugates Forecast
- 12.6 Asia Pacific Antibody Drug Conjugates Forecast
- 12.7 Central & South America Antibody Drug Conjugates Forecast
- 12.8 Middle East and Africa Antibody Drug Conjugates Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Antibody Drug Conjugates Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Antibody Drug Conjugates . Industry analysis & Market Report on Antibody Drug Conjugates is a syndicated market report, published as Global Antibody Drug Conjugates Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Antibody Drug Conjugates market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
